Abstract
The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid β-peptide. RAGE has a secretory splice isoform, soluble RAGE (sRAGE), that lacks the transmembrane domain and therefore circulates in plasma. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease, hypertension, the metabolic syndrome, arthritis and Alzheimers disease. Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent vascular damage and neurodegeneration. This review presents the state of the art in the use of sRAGE as a disease marker and discusses the therapeutic potential of targeting sRAGE for the treatment of inflammationrelated diseases such as atherosclerosis, arthritis and Alzheimers disease.
Keywords: receptor for advanced glycation end products, inflammation, neurodegeneration, atherosclerosis, metabolic, syndrome, hypertension, arthritis, Alzheimer's disease, biomarker
Current Medicinal Chemistry
Title: Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target
Volume: 13 Issue: 17
Author(s): Diego Geroldi, Colomba Falcone and Enzo Emanuele
Affiliation:
Keywords: receptor for advanced glycation end products, inflammation, neurodegeneration, atherosclerosis, metabolic, syndrome, hypertension, arthritis, Alzheimer's disease, biomarker
Abstract: The receptor for advanced glycation end products (RAGE) is a cell-bound receptor of the immunoglobulin superfamily which may be activated by a variety of proinflammatory ligands including advanced glycoxidation end products, S100/calgranulins, high mobility group box 1, and amyloid β-peptide. RAGE has a secretory splice isoform, soluble RAGE (sRAGE), that lacks the transmembrane domain and therefore circulates in plasma. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. Clinical studies have recently shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease, hypertension, the metabolic syndrome, arthritis and Alzheimers disease. Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent vascular damage and neurodegeneration. This review presents the state of the art in the use of sRAGE as a disease marker and discusses the therapeutic potential of targeting sRAGE for the treatment of inflammationrelated diseases such as atherosclerosis, arthritis and Alzheimers disease.
Export Options
About this article
Cite this article as:
Geroldi Diego, Falcone Colomba and Emanuele Enzo, Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target, Current Medicinal Chemistry 2006; 13 (17) . https://dx.doi.org/10.2174/092986706777585013
DOI https://dx.doi.org/10.2174/092986706777585013 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Editorial [Hot topic: Proteinuria in Diabetes: an Endocrine Disease? (Guest Editor: Alessia Fornoni and Oliver Lenz)]
Current Diabetes Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Discovery of Potent, Non-Steroidal and Highly Selective Glucocorticoid Receptor Antagonists with Anti-Obesity Activity
Letters in Drug Design & Discovery Design, Synthesis, Molecular Docking Study and Anti-Hepatocellular Carcinoma Evaluation of New Bis-Triazolothiadiazines
Mini-Reviews in Medicinal Chemistry Alstrom Syndrome: Genetics and Clinical Overview
Current Genomics Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention (Discontinued) Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Technological Options for the Production of Health-Promoting Proteins and Peptides Derived from Milk and Colostrum
Current Pharmaceutical Design Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments
Current Pharmaceutical Design Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery